New hope: pill aims to wipe out hidden breast cancer cells
NCT ID NCT07631052
First seen Jun 09, 2026 · Last updated Jun 12, 2026 · Updated 1 time
Summary
This study tests whether the chemotherapy drug capecitabine can clear tiny traces of cancer DNA found in the blood of people with ER+/HER2- breast cancer after standard treatment. About 15 adults whose cancer has been surgically removed but still show signs of residual disease will take capecitabine pills daily for up to 12 months. The goal is to see if this approach can prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHN - Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.